BBIO BridgeBio Pharma
- 27.610
- +0.380+1.40%
- 27.550
- -0.060-0.22%
BridgeBio Pharma News
BridgeBio Surpasses Interim Analysis Enrollment Target in Limb-Girdle Muscular Dystrophy Trial
BridgeBio Pharma (BBIO) said Tuesday it surpassed its interim analysis enrollment target for its phase 3 study of BBP-418 in people with limb-girdle muscular dystrophy type 2I/R9, with top-line result
Express News | BridgeBio Pharma Inc: Top-Line Results From Interim Analysis Expected in 2025
Express News | BridgeBio Pharma Inc: FDA Has Granted Rare Pediatric Disease Designation (Rpdd) for Bbp-418 in Treatment of Lgmd2I/R9
Express News | BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for Bbp-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (Lgmd2I/R9)
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
J.P. Morgan analyst Anupam Rama maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 45.5% and a
Citi Opens Upside Catalyst Watch on Alnylam Ahead of ATTR-CM Data
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases an
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
PALO ALTO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases an
BridgeBio Pharma(BBIO.US) Director Sells US$75,792.52 in Common Stock
$BridgeBio Pharma(BBIO.US)$ Director Scott Randal W. sold 2,500 shares of common stock on Jun 3, 4, 2024 at an average price of $30.317 for a total value of $75,792.52.Source: Announcement What is sta
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
NEW YORK--(BUSINESS WIRE)--$BBIO #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of BridgeBio Pharma, Inc. ("BridgeBio"
BMO Capital Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $37
BMO Capital analyst Kostas Biliouris maintains $BridgeBio Pharma(BBIO.US)$ with a hold rating, and maintains the target price at $37.According to TipRanks data, the analyst has a success rate of 32.1%
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $50
BofA Securities analyst Jason Zemansky maintains $BridgeBio Pharma(BBIO.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 67.9
A Quick Look at Today's Ratings for BridgeBio Pharma(BBIO.US), With a Forecast Between $37 to $58
On Jun 05, major Wall Street analysts update their ratings for $BridgeBio Pharma(BBIO.US)$, with price targets ranging from $37 to $58.Goldman Sachs analyst Salveen Richter maintains with a buy rating
Express News | HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $43 Price Target
BridgeBio Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/05/2024 54.4% HC Wainwright & Co. $43 → $43 Reiterates Buy → Buy 05/30/2024 54.4% HC Wainwright & Co. $
Express News | BridgeBio Pharma Inc : JP Morgan Raises Target Price to $46 From $44
BridgeBio Pharma Shares One Year Data From Dwarfism Candidate
Tuesday, BridgeBio Pharma Inc (NASDAQ:BBIO) announced sustained results from the PROPEL 2 Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, a disorder of bone
Why BridgeBio Pharma Stock Is Trading Lower Tuesday
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is moving lower Tuesday after the company announced results from its Phase 2 trial of infigratinib in children with achondroplasia.What Happened: The results showe
Express News | BridgeBio Pharma Shares up 5.9% on Positive Mid-Stage Trial for Genetic Bone Condition Treatment
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday
Health care stocks were steady pre-bell Tuesday, with the Health Care Select Sector SPDR Fund (XLV) and iShares Biotechnology ETF (IBB) each recently inactive. Annexon (ANNX) rallied more than 37% aft
Analysis
Price Target
No Data
